Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (PRO-SID” study)

Phase 1

• Conditions: Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia; MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864; Therapeutic area: Diseases [C] - Cancer [C04]

• Registration Number: EUCTR2019-004375-40-DE
• Lead Sponsor: Octapharma Pharmazeutika Produktionsges.m.b.H.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-02-21
• Last Update Posted: 13 December 2021

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 450

Inclusion Criteria

1. Treatment-naïve or relapsed/refractory CLL patients undergoing CLL antineoplastic treatment. Diagnosis of B-cell CLL established according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria and documented within medical records.
2. Hypogammaglobulinemia (IgG levels <5 g/L) as confirmed by the Central Laboratory.
3. =18 years of age.
4. Voluntarily given, fully informed written and signed consent obtained before any study-related procedures are conducted.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 225
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 225

Exclusion Criteria

1. IgG treatment within 3 months prior to Screening.
2. Antibiotic prophylaxis and/or treatment within 7 days prior to current CLL treatment start (with the exception of trimethoprim-sulfamethoxazole [TMP/SMX], diaminodiphenyl sulfone [dapsone] and pentamidine inhalation).
3. Current major infection or >1 major infection in the previous 6 months before Baseline.
4. History of anaphylaxis or severe systemic response to immunoglobulin, blood or plasma-derived products or any Panzyga component.
5. History of a non-CLL malignancy with life-expectancy of less than two years.
6. Severe liver disease, with signs of ascites and/or hepatic encephalopathy.
7. Severe kidney disease (as defined by estimated glomerular filtration rate [eGFR] <30 mL/min/1.73 m2).
8. Body weight >140 kg.
9. Eastern Cooperative Oncology Group (ECOG) performance score of >2 (Appendix 1).
10. Female patients of childbearing potential unwilling to use a protocol-required method of contraception from the Screening Visit throughout the study treatment period and for 30 days following the last dose of study drug.
11. Human immunodeficiency virus (HIV) infection at Screening (defined
for the study as positive HIV antibody test).
12. Patients found to be chronic carriers of hepatitis B virus (HBV),
defined by positive surface antigen (HBsAg), positive Hepatitis B core
antibodies (HBcAb) and/or low HBV titers, who will not receive targeted
antiviral therapy while undergoing CLL therapy, and patients with active
HBV, defined as high HBV titers
13. Uncontrolled hepatitis C infection at Screening (defined for the study as positive hepatitis virus C [HCV] polymerase chain reaction [PCR]).
14. Pregnant and lactating women.
15. Subjects with a history of thromboembolic events (TEE) such as deep vein thrombosis, pulmonary embolism, myocardial infarction, ischemic stroke, transient ischemic attack, peripheral artery disease (Fontaine IV) within 6 months before Baseline.
16. Planned or ongoing immunosuppressive treatment (other than for CLL or corticosteroids) or other forbidden medication during the entire study duration after study enrollment.
17. Participation in another interventional clinical trial that is either blinded or involves an investigational (not approved) product within 3 months before Baseline or during the course of the clinical study. Participation in observational clinical trials or open-label trials involving an approved product may be permitted after consultation with the medical monitor.
18. Known IgA deficiency with antibodies to IgA (as part of the patient´s medical history).
19. Known blood hyperviscosity, or other hypercoagulable states.
20. Patients unable or unwilling to understand or comply with the study protocol.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified